The PSMA scan is indicated for patients with primary prostate cancer and for patients with biochemical recurrence of PSA after radical surgery.
PET/CT is one of the most advanced medical imaging devices, using the distribution of radioisotopes in different tissues and organs, and using nuclide imaging to see changes in cellular function inside the body that cannot be observed with the “naked eye” and to show abnormal lesions. Therefore, PET/CT has become a valuable screening device for clinical malignancy screening, benign and malignant differentiation, and efficacy assessment.
Prostate specific membrane antigen (PSMA) is a type II intrinsic membrane protein found in the cytosol of prostate gland epithelial cells. The PSMA is a commonly used tissue-specific expression antigen for prostate cancer.
In recent years, the diagnosis and treatment of various prostate cancers based on PSMA as a carrier has become a hot topic of research, and the significance of PSMA PET/CT scanning in the diagnostic staging and recurrence monitoring of prostate cancer has been well recognized.
Clinically, PSMA scans can be used for systemic assessment of staging in patients with primary prostate cancer, to determine metastases and recurrence in patients with biochemical PSA recurrence after radical surgery, to find metastases and primary foci in patients with hormone-resistant prostate cancer, and for observation of efficacy after radiotherapy with higher sensitivity and specificity than the scans commonly used in clinical practice.